Harvard Bioscience sets Q3 revenue target at $19M-$21M, CEO outlines priorities for 2025.

Harvard Bioscience has outlined a Q3 revenue target of $19M-$21M. The company's debt refinancing is advancing and product adoption is accelerating. New CEO John Duke is prioritizing financial discipline, innovation, and culture for the remainder of 2025.

Harvard Bioscience (HBIO) has outlined a third-quarter (Q3) revenue target of $19 million to $21 million, according to its recent earnings call. The company's debt refinancing efforts are progressing, and product adoption is accelerating, reflecting a strategic focus on financial discipline and innovation under the leadership of new CEO John Duke.

The company reported mixed results for the second quarter (Q2) 2025, with revenue of $20.5 million, a 11.5% year-over-year (YoY) decline, and earnings per share (EPS) of -$0.01, missing analyst expectations by a wider margin. However, the company's adjusted EBITDA improved to $1.5 million from $1.3 million in the same period last year, driven by operational efficiencies [1].

John Duke, the newly appointed CEO, emphasized the company's priorities for the remainder of 2025, including financial discipline, innovation, and culture. He highlighted the company's focus on restructuring debt obligations and using the balance sheet to invest in business growth. The company aims to improve its gross margin and maintain operational resilience despite market challenges [2].

The company's strategic initiatives, such as the launch of the SOHO telemetry platform and the expansion of the MeSH MEA organoid platform, are expected to drive future growth. Additionally, the company is optimistic about improved NIH funding and academic purchasing in 2026, which could further boost revenue [2].

The stock market's reaction to the earnings report was relatively stable, with a pre-market dip of just 0.23% to $0.527, despite the earnings miss. The stock has demonstrated significant momentum with a 21.3% return over the past week but remains down nearly 75% year-to-date [2].

References:
1. [1] https://seekingalpha.com/news/4483108-harvard-bioscience-beats-top-line-and-bottom-line-estimates-initiates-q3-outlook
2. [2] https://ng.investing.com/news/transcripts/earnings-call-transcript-harvard-bioscience-q2-2025-results-show-mixed-signals-93CH-2055614